

Prescriber Criteria Form

Zelboraf 2025 PA Fax 696-A v1 010125.docx  
 Zelboraf (vemurafenib)  
 Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Zelboraf (vemurafenib).

Drug Name:  
 Zelboraf (vemurafenib)

<b>Patient Name:</b>		
<b>Patient ID:</b>		
<b>Patient DOB:</b>	<b>Patient Phone:</b>	
<b>Prescriber Name:</b>		
<b>Prescriber Address:</b>		
<b>City:</b>	<b>State:</b>	<b>Zip:</b>
<b>Prescriber Phone:</b>	<b>Prescriber Fax:</b>	
<b>Diagnosis:</b>	<b>ICD Code(s):</b>	

<b>Please circle the appropriate answer for each question.</b>			
1	Does the patient have a diagnosis of melanoma? [If no, then skip to question 6.]	Yes	No
2	Will the requested medication be used for the adjuvant treatment of melanoma? [If yes, then skip to question 4.]	Yes	No
3	Is the melanoma unresectable, limited resectable, or metastatic? [If no, then no further questions.]	Yes	No
4	Is the tumor positive for BRAF V600 activating mutation (e.g., V600E or V600K)? [If no, then no further questions.]	Yes	No
5	Will the requested drug be used as a single agent or in combination with cobimetinib? [No further questions.]	Yes	No
6	Does the patient have a diagnosis of central nervous system (CNS) cancer (i.e., glioma, glioblastoma, pediatric diffuse high-grade glioma)? [If no, then skip to question 10.]	Yes	No
7	Is the tumor positive for BRAF V600E mutation? [If no, then no further questions.]	Yes	No

8	Is the requested drug being used for the treatment of pediatric diffuse high-grade glioma? [If yes, then no further questions.]	Yes	No
9	Will the requested drug be used in combination with cobimetinib? [No further questions.]	Yes	No
10	Does the patient have a diagnosis of Erdheim-Chester Disease (ECD) or Langerhans Cell Histiocytosis? [If no, then skip to question 12.]	Yes	No
11	Is the disease positive for a BRAF V600 mutation? [No further questions.]	Yes	No
12	Does the patient have a diagnosis of non-small cell lung cancer (NSCLC)? [If no, then skip to question 15.]	Yes	No
13	Is the disease recurrent, advanced, or metastatic? [If no, then no further questions.]	Yes	No
14	Is the tumor positive for a BRAF V600E mutation? [No further questions.]	Yes	No
15	Does the patient have a diagnosis of hairy cell leukemia?	Yes	No

Comments:	
-----------	--

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

<b>Prescriber (or Authorized) Signature:</b> _____	<b>Date:</b> _____
--	--------------------